Significant improvements in cortical and trabecular bone tissue are seen in patients with osteoporosis treated with romosozumab. This was revealed by the abstracts of three post-hoc analyzes centered on 3D modeling techniques presented, together with 17 other abstracts, at the 2022 annual congress of the American society for bone and mineral research (Asbmr), recently concluded in Austin (Texas, USA) . This was announced in a well-known Ucb biopharmaceutical company that has developed, with Amgen, the drug, a monoclonal antibody which, by inhibiting the activity of sclerostin, determines, on the one hand, an increase in bone formation and, to a lesser extent, a reduction in resorption. of bone tissue.
Osteoporosis is the most common chronic metabolic bone disease characterized by impaired strength of the bone. The condition causes approximately 9 million fractures each year. Fragility fractures bring considerable discomfort to a person’s life, often making daily activities such as eating, dressing, grocery shopping, or driving difficult. In the analyzes – reads the note – the researchers used three-dimensional modeling based on Dxa of the hip to evaluate bone changes and map the distribution of mutations in bone tissue parameters over time, in patients enrolled in the Frame, Arch and Structure studies. . The three-dimensional modeling based on Dxa (Dual-energy X-ray Absorptiometry) allows to estimate the cortical and trabecular bone parameters in a way comparable to the Qct (Quantitative computed tomography) measurements and to formulate outputs to visualize and monitor the treatment of osteoporosis.
In the abstract Structure (Lewiecki et al.) 3D modeling from Dxa hip scans was analyzed in postmenopausal women with osteoporosis who had received oral bisphosphonate therapy for more than 3 years and alendronate for more than 1 year. year prior to screening, who were randomized to receive romosozumab or a control / comparator drug (teriparatide) for 12 months. Patients treated with romosozumab achieved greater increases in cortical volumetric Bone mineral density (CvBmd), cortical thickness (Cth), cortical superficial Bmd (CsBmd) and trabecular volumetric Bmd (TvBmd), compared to to the control groups, as early as month 6 through month 12. The results also showed that treatment with teriparatide led to a loss of CvBmd, Cth and CsBmd.
Another abstract – also by Leiwiecki and colleagues – reported the results of a post-hoc analysis of the Frame and Arch studies. Postmenopausal women with osteoporosis were randomized to romosozumab 210 mg per month or to a comparator (Frame: placebo; Arch: alendronate 70 mg) for 12 months. After this time period, all patients received denosumab in Frame or alendronate in Arch. 3D modeling of the Dxa hip scans showed that at month 12, treatment with romosozumab versus placebo (Frame) and versus alendronate ( Arch) resulted in a greater increase in cortical volumetric bone mineral density (CvBmd), cortical thickness (Cth), superficial cortical Bmd (CsBmd) and trabecular volumetric Bmd (TvBmd). At month 24, cumulative gains in density parameters were greater in the romosozumab / denosumab sequence compared to placebo / denosumab (P <0.001) and in the romosozumab / alendronate sequence compared to alendronate alone (P <0.05).
These data further confirm previous studies (Cosman et al. And McClung et al.) Which have shown a greater increase in bone mineral density (Bmd), a reduction in the incidence of new vertebral fractures and a lower incidence of clinical, non-vertebral fractures, respectively. and hip with romosozumab / denosumab treatment and a significant improvement in bone microarchitecture with romosozumab / alendronate treatment.
“With the lengthening of lifespan, the prevalence of osteoporosis is on the rise. Despite this, this condition remains largely under-diagnosed and under-treated. For this reason it is encouraging to see new analyzes that reinforce the superiority of romosozumab as a treatment option. treatment for postmenopausal women with severe osteoporosis at high risk of fragility fractures – says Emmanuel Caeymaex, Executive Vice President, Immunology solutions & Head of Us of Ucb -. Asbmr 2022 is a very important congress for physicians and scientists from all over the world, who can share the latest discoveries and innovations. For this reason, we at UCB are proud to participate this year with a wide range of scientific studies. Our goal is to ensure that the treatment of osteoporosis be a priority now and in the future to continue improving patient outcomes. “